• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes in non-alcoholic fatty liver disease.

作者信息

Huang Rui, Wu Weihua, Wang Jian, Zhang Zhaoping, Wu Chao

机构信息

Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

出版信息

Aliment Pharmacol Ther. 2019 Aug;50(3):338. doi: 10.1111/apt.15362.

DOI:10.1111/apt.15362
PMID:31313357
Abstract
摘要

相似文献

1
Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes in non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2019 Aug;50(3):338. doi: 10.1111/apt.15362.
2
Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes non-alcoholic fatty liver disease-authors' reply.信函：使用胶原比例面积来量化肝纤维化并预测非酒精性脂肪性肝病的临床结局——作者回复
Aliment Pharmacol Ther. 2019 Aug;50(3):339. doi: 10.1111/apt.15385.
3
Editorial: collagen proportionate area as a prognostic indicator in NAFLD.
Aliment Pharmacol Ther. 2019 Jun;49(11):1452-1454. doi: 10.1111/apt.15249.
4
Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者中无创性纤维化模型预测轻度至中度纤维化的性能。
Liver Int. 2016 Apr;36(4):572-9. doi: 10.1111/liv.13054. Epub 2016 Jan 24.
5
Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.通过单克隆抗体检测血清免疫反应性胶原蛋白IV作为非酒精性脂肪性肝病患者严重纤维化的标志物。
J Gastrointestin Liver Dis. 2015 Mar;24(1):61-8. doi: 10.15403/jgld.2014.1121.yad.
6
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.隐匿性肝硬化的难题：无治疗选择的不良结局。
J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.
7
An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.一项探索性研究，考察纳米液相色谱-质谱联用和磷酸化蛋白质组学如何区分非酒精性脂肪性肝病中晚期纤维化和更高百分比胶原的患者。
BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.
8
The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.γ-谷氨酰转肽酶与血小板比值用于慢性乙型肝炎和非酒精性脂肪性肝病患者肝纤维化的无创评估
Oncotarget. 2017 Apr 25;8(17):28641-28649. doi: 10.18632/oncotarget.16162.
9
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.诊断非酒精性脂肪性肝病/非酒精性脂肪性肝炎：非侵入性检查足矣。
Liver Int. 2018 Feb;38 Suppl 1:67-70. doi: 10.1111/liv.13658.
10
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.西妥昔单抗对非酒精性脂肪性肝炎引起的桥接纤维化或代偿性肝硬化患者无效。
Gastroenterology. 2018 Oct;155(4):1140-1153. doi: 10.1053/j.gastro.2018.07.006. Epub 2018 Jul 7.